Print page

Catalent Awarded for H1N1 Project with GSK

PharmaManufacturing.com
10/20/2009

Catalent Pharma Solutions, a leading provider of outsourced clinical and commercial packaging services to the global pharmaceutical and biotechnology industry, has won for the second year in a row “The Best Contract Manufacturing Project” award at this year’s European Outsourcing Awards ceremony. Catalent was recognized for supporting GlaxoSmithKline’s efforts to meet global demand for a key antiviral drug recommended to treat H1N1 influenza.

“As part of GlaxoSmithKline's response to the global pandemic, it was necessary to rapidly expand manufacture and supply of Relenza, a major antiviral product,” said Jim Brown, Director, External Supply Pharmaceuticals Europe for GSK. “While it was possible to rapidly increase manufacturing capacity internally within GSK sites, there was insufficient capacity for packaging to meet worldwide demand. Catalent was able to respond rapidly to this requirement, freeing up equipment, increasing shift patterns and providing a very effective packaging operation to secure early availability of this critical medicine.”

“We were very pleased to partner with GlaxoSmithKline in helping them meet increasing demand for their product, and we look forward to working with them in the future,” said Steve Facer, Site General Manager of Catalent’s Packaging Services facility in Corby, England. “We are also delighted to once again win this prestigious award.”

Launched in 2005, the European Outsourcing Awards recognize significant developments in contract services and rewards successful companies for their outstanding contributions and achievements throughout the year. The awards were created to celebrate and recognize excellence in R&D, marketing, business and technology across the pharmaceutical industry.

About Catalent
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,500 people at 30 facilities worldwide and in fiscal 2009 generated more than $1.6 billion in annual revenue. For more information, visit www.catalent.com.